• Ysios portfolio company Ona Therapeutics reported rapid enrollment in its Phase 1a dose-escalation trial of lead ADC ONA-255.
• Aleix Prat was appointed chief medical officer as ONA-255 advances in HR+/HER2-negative advanced breast cancer, metastatic gastric cancer.
• Jutta Amersdorffer shifted to chief development officer to lead development execution across ONA-255, pipeline programs.
• Update follows Ona’s USD 86.6 million Series B financing earlier this year.
• Pipeline progress includes ONA-389 in IND-enabling studies, targeted for clinic entry in the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ysios Capital Partners SGEIC SA published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.